LAB · Standard Biotools Inc. · Executive Compensation
$0.63
+0.02 (+2.82%)
At close · Nov 20
Return incl. dividend (before tax)
Q1 2025 earnings call transcript
Market Cap
$249.11M
Shares
394.79M
Volume · Nov 20
2.81M
Avg daily vol (3M)
1.2M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Michael Egholm | President, Chief Executive Officer, and Director | $8,823,502 |
| Alex Kim | Chief Financial Officer | $4,005,165 |
| Sean Mackay | Chief Business Officer | $1,692,543 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Michael Egholm | President, Chief Executive Officer, and Director | $8,337,044 |
| Sean Mackay | Chief Business Officer | $3,177,155 |
| Alex Kim | Chief Financial Officer | $3,090,340 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Michael Egholm | President, Chief Executive Officer, and Director | $1,931,088 |
| Jeffrey G. Black | Former Chief Financial Officer | $1,492,297 |
| Alex Kim | Chief Financial Officer | $909,788 |
| Sean Mackay | Chief Business Officer | — |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Michael Egholm | President, Chief Executive Officer, and Director | $15,895,848 |
| Alex Kim | Chief Financial Officer | $5,856,938 |
| Stephen Christopher Linthwaite | Former President and CEO | $1,638,601 |
| Jeremy Davis | Chief Commercial Officer | $1,404,172 |
| Jeffrey G. Black | Former Chief Financial Officer | — |
| Sean Mackay | Chief Business Officer | — |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Stephen Christopher Linthwaite | Former President and CEO | $3,311,662 |
| Colin McCracken | Former Chief Commercial Officer | $1,386,353 |
| Vikram Jog | Chief Financial Officer | $1,105,664 |
| Nicholas Khadder | Senior Vice President, General Counsel, and Secretary | $920,559 |
| Bradley Kreger | Senior Vice President, Global Operations | $894,346 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Stephen Christopher Linthwaite | Former President and CEO | $3,800,867 |
| Colin McCracken | Former Chief Commercial Officer | $1,657,454 |
| Vikram Jog | Chief Financial Officer | $1,443,226 |
| Bradley Kreger | Senior Vice President, Global Operations | $1,385,499 |
| Nicholas Khadder | Senior Vice President, General Counsel, and Secretary | $1,050,529 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Stephen Christopher Linthwaite | Former President and CEO | $3,713,055 |
| Colin McCracken | Former Chief Commercial Officer | $1,911,764 |
| Vikram Jog | Chief Financial Officer | $1,391,445 |
| Bradley Kreger | Senior Vice President, Global Operations | $1,352,299 |
| Nicholas Khadder | Senior Vice President, General Counsel, and Secretary | $1,257,775 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Stephen Christopher Linthwaite | President and CEO | $2,585,213 |
| Vikram Jog | Chief Financial Officer | $1,125,539 |
| Nicholas Khadder | Senior Vice President, General Counsel, and Secretary | $1,091,461 |
| Bradley Kreger | Senior Vice President, Global Operations | $995,197 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Stephen Christopher Linthwaite | President and CEO | $2,019,870 |
| Vikram Jog | Chief Financial Officer | $974,126 |
| Nicholas Khadder | Senior Vice President, General Counsel, and Secretary | $925,210 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Eli Casdin | Class I director |
Already on the board
Since at least 2022: re-election or new board role
|
2026-06-18 |
| Thomas Carey | Class I director |
Already on the board
Since at least 2024: re-election or new board role
|
2026-06-18 |
| Michael Egholm, Ph.D. | Class I director | Appointed | 2026-06-18 |
| Spencer Smith | Chief Financial Officer | Appointed | 2026-06-08 |
| Dr. Jeff Engelman | Chief Scientific Officer | Appointed | 2026-06-08 |
| Dr. Josh Bilenker | Chief Executive Officer | Appointed | 2026-06-08 |
| Frank Witney, Ph.D. | Class III director | Appointed | 2025-06-20 |
| Kathy Hibbs | Class III director | Appointed | 2025-06-20 |
| Jeremy Davis | Chief Commercial Officer | Terminated | 2025-01-10 |
| Alex Kim | Chief Financial Officer | Appointed | 2024-11-07 |
| Alex Kim | Interim Chief Financial Officer | Appointed | 2024-07-31 |
|
Jeffrey Black
“Mr. Black’s resignation was not due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices, and was driven by his desire to accept an opportunity at another public company.”
|
Senior Vice President and Chief Financial Officer | Resigned | 2024-07-31 |
| Fenel M. Eloi | Class II director | Appointed | 2024-07-01 |
| Troy Cox | Class II director | Appointed | 2024-07-01 |
|
Martin Madaus
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2024-01-05 |
|
Carlos Paya
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
Board of Directors | Resigned | 2024-01-05 |
| Shane Bowen | Chief Technology Officer | Appointed | 2024-01-05 |
| Adam Taich | Chief Strategy Officer | Appointed | 2024-01-05 |
| Troy Cox | director | Appointed | 2024-01-05 |
| Tom Carey | Chairperson of the Standard BioTools Board | Appointed | 2024-01-05 |
| Tom Carey | director | Appointed | 2024-01-05 |
| Kathy Hibbs | director | Appointed | 2024-01-05 |
|
Martin Madaus, Ph.D.
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
director | Resigned | 2024-01-05 |
|
Laura Clague
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
director | Resigned | 2024-01-05 |
|
Carlos Paya, M.D., Ph.D.
“No director resigned as a result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”
|
director | Resigned | 2024-01-05 |
Leadership
- Dr. Josh Bilenker CEO
- Dr. Michael Egholm CEO
- Michael Egholm CEO, Board Member
- Carlos Paya Chairman
- Tom Carey Chairman, Board Member
- Alex Kim CFO, COO
- Spencer Smith CFO
- Hanjoon Alex Kim COO
- Shane Bowen CTO
- Jonathan Mickelsen Chief Accounting Officer
- Ana K. Stankovic Board Member
- Ana K. Stankovic, M.D., Ph.D., MSPH Board Member
- Eli Casdin Board Member
- Fenel Eloi Board Member
- Fenel M. Eloi Board Member
- Frank Witney Board Member
- Frank Witney, Ph.D. Board Member
- Gerhard F. Burbach Board Member
- Kathy Hibbs Board Member
- Martin Madaus Board Member
- Michael Egholm, Ph.D. Board Member
- Nicolas M. Barthelemy Board Member
- Thomas Carey Board Member
- Troy Cox Board Member
Key facts
CIK
1162194
CUSIP
34385P108
13F (30d)
121 filings
100 filers
Visit website
Investor relations